Sands Capital Discloses 6.3% Stake in Alamar Biosciences Post-IPO
ALMR is trading near its 52-week low of $21.75 (9.0% above the low) on light trading volume (0.3× avg).
Summary
Sands Capital has reported a substantial 6.3% ownership in Alamar Biosciences, Inc. following its IPO, demonstrating significant institutional backing for the new public entity.
Key Events · Ownership and Investor Activity · ALMR
-
Major Institutional Stake Established
Sands Capital Life Sciences Pulse Fund II, L.P. reported a 6.3% beneficial ownership of Alamar Biosciences' common stock, totaling 4,230,926 shares.
-
Post-IPO Investment
The stake was primarily acquired through the conversion of pre-IPO preferred stock and a convertible note, along with a direct purchase of 300,000 shares at the IPO price of $17.00 per share.
-
Board Representation
An Executive Managing Partner from Sands Capital, Ian Ratcliffe, serves on the Issuer's board of directors, indicating active involvement.
Analysis · ALMR · Industrial Applications And Services
Sands Capital Life Sciences Pulse Fund II, L.P. has disclosed a significant 6.3% beneficial ownership stake in Alamar Biosciences, Inc. following its recent initial public offering. This stake, valued at approximately $71.9 million based on the IPO price, or over $100 million at the current market price, signals strong institutional confidence in the newly public company. The investment firm's Executive Managing Partner also holds a board seat, indicating active engagement and a long-term commitment.
At the time of this filing, ALMR was trading at $23.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $21.75 to $25.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.